A simple blood draw could catch cancer years before symptoms appear
From a laboratory in Mumbai, born partly from personal grief, a new blood test called HrC quietly reframes one of medicine's oldest struggles: catching cancer not when it announces itself through suffering, but long before. Developed by Epigeneres Biotechnology and Tzar Labs, the test asks only for a small vial of blood and returns answers within days, potentially detecting any of 180 known cancer types. In a country where one in nine people will face cancer in their lifetime, and across a world where nearly ten million died of the disease in a single year, the question this innovation poses is not merely scientific — it is deeply human: how much suffering might be spared if we learned to listen to the blood before the body begins to break?
- Cancer claims nearly 10 million lives a year globally, yet most cases are still caught too late — after symptoms have already surrendered the advantage of early treatment.
- India faces a compounding crisis, with breast and colorectal cancers rising alongside lifestyle shifts, and millions lacking access to the sophisticated diagnostics that early detection demands.
- HrC cuts through that barrier with startling simplicity: five milliliters of blood, molecular analysis, and results in three to four days — no invasive procedures, no specialist equipment beyond the reach of ordinary clinics.
- The test detected 25 cancer types across a 1,000-person study, drawing from a theoretical range of 180 known cancers, and its developers believe automation could compress the turnaround to just two days.
- The innovation now stands at its most critical threshold — moving from peer-reviewed promise into the hospitals and health centers where it could actually reach the one in nine Indians whose lives may one day depend on it.
Two biotechnology firms — Epigeneres Biotechnology in Mumbai and Tzar Labs in Singapore — have developed a blood test capable of detecting cancer before a single symptom appears. Named HrC, the test requires only five milliliters of blood and returns results within three to four days, with the potential to identify any of 180 known cancer types through molecular analysis. A study of 1,000 people, published in a peer-reviewed journal, successfully detected 25 different cancers.
The test carries a quiet grief at its center. HrC bears the initials of Himanshu Roy, son-in-law of one of the developers, who died of cancer in 2018. What might have remained an abstract scientific ambition was sharpened by personal loss into something urgent and human.
The stakes are considerable. One in nine Indians will develop cancer over their lifetime, according to international health research, and rising rates of breast and colorectal cancer are tied to shifting lifestyles across the country. Globally, nearly 10 million people died of cancer in 2020 alone. Early detection, the World Health Organization has long affirmed, dramatically improves survival — but only if the tools to achieve it are accessible.
This is where HrC's simplicity becomes its most powerful argument. Unlike complex screening procedures, a small blood draw requires no invasive steps and could scale across clinics that currently lack advanced diagnostic infrastructure. Developers believe automation could reduce testing time to two days. The harder journey now begins: translating laboratory success into the hospitals and communities where the test might finally reach the people who need it most.
Two biotechnology companies—one based in Mumbai, the other in Singapore—have created a blood test that can identify cancer before a person feels sick. The test, called HrC, represents a shift in how we might catch one of the world's deadliest diseases: not after symptoms force someone to a doctor, but years earlier, when treatment stands the best chance of working.
Cancer kills more people globally than almost any other disease. It begins when cells in the body start multiplying in ways they shouldn't, breaking the normal cycle where old cells die and healthy new ones replace them. DNA mutations drive this chaos, and those mutations can be inherited or acquired over a lifetime. The earlier doctors catch it, the better the odds of saving a life. This is not new knowledge. What is new is a practical way to find it hiding in the bloodstream before symptoms announce its presence.
Epigeneres Biotechnology, based in Mumbai, partnered with Tzar Labs in Singapore to develop the test. Their work, published in the peer-reviewed journal Stem Cell Reviews and Reports, describes a straightforward process: a patient gives five milliliters of blood—less than a teaspoon. The sample undergoes molecular analysis. The test can theoretically identify any of 180 known cancer types. In their study of 1,000 people, the researchers detected 25 different kinds of cancer. Results come back in three to four days, though the developers believe automation could cut that to two days.
The test carries a personal story. Himanshu Roy, the son-in-law of one of the developers, died of cancer in 2018. The test bears his initials—HrC—a reminder that this work emerged not from abstract ambition but from loss. The developer told journalists that the test is simple enough that anyone can do it, and the speed matters: early diagnosis, according to the World Health Organization, improves outcomes by catching disease at its most treatable stage.
The numbers underscore why this matters. One in nine Indians will develop cancer at some point in their lives, according to the International Agency for Research on Cancer. Breast and colorectal cancers are rising, linked to weight gain, sedentary habits, and lifestyle factors. Globally, nearly 10 million people died of cancer in 2020 alone. If a blood test could catch even a fraction of these cases earlier, it could reshape survival rates across a country where millions lack access to advanced diagnostic tools. The test's simplicity—requiring only a small blood sample and no invasive procedures—makes it potentially scalable in ways that more complex screening methods are not. What comes next is whether this innovation can move from the laboratory into clinics and hospitals where it might actually reach the people who need it most.
Citações Notáveis
The test is super simple and would take 3-4 days to get results, but automation advancements can bring it down to 2 days— Developer Tripathi, speaking to NDTV
Early diagnosis can help improve outcomes by providing care at the earliest possible stage— World Health Organization
A Conversa do Hearth Outra perspectiva sobre a história
Why does this test matter more than other cancer screening methods that already exist?
Most screening tests look for one or two specific cancers—mammograms for breast cancer, colonoscopies for colorectal cancer. This one can theoretically identify 25 different types from a single blood draw. It's non-invasive, which means no colonoscopy, no radiation, just blood. And it works before symptoms show up, when treatment is most effective.
But can it actually do all that, or is this still mostly promise?
The paper shows they tested it on 1,000 people and found 25 cancer types. That's real data, not speculation. But 1,000 people is a starting point. You'd need much larger studies to know how accurate it is across different populations and cancer stages.
Why name it after someone who died?
Because Himanshu Roy was the developer's son-in-law. He died of cancer in 2018. This test exists because someone lived through that loss and decided to build something that might prevent others from having to.
If it works, what's the barrier to getting it into hospitals?
Regulatory approval, manufacturing scale, cost, and whether it's actually as accurate as early results suggest. A blood test that works in a lab doesn't automatically work in a clinic with thousands of different patients.
What would it mean if it did work at scale?
In a country where 1 in 9 people will get cancer, and many can't afford advanced imaging or don't have access to it, a simple blood test could catch disease years earlier. That's the difference between survival and not.